Intraperitoneal carboplatin in icodextrin 4% as first-line treatment for epithelial ovarian cancer: A phase I/II trial

被引：0
|
作者：
Hofman, L.
Sludden, J.
Boddy, A. V.
Murphy, D. J.
Ferry, D. R.
机构：
[1] Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
[2] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England
[3] New Cross Hosp, Wolverhampton, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5522
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
    Burris, H
    Yardley, D
    Jones, S
    Houston, G
    Broome, C
    Thompson, D
    Greco, FA
    White, M
    Hainsworth, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1621 - 1629
  • [32] Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer - A multicenter phase II trial
    Potamianou, A
    Androulakis, N
    Papakotoulas, P
    Toufexi, H
    Latoufis, C
    Kouroussis, C
    Christofilakis, C
    Xenidis, N
    Georgoulias, V
    Polyzos, A
    [J]. ONCOLOGY, 2005, 69 (04) : 348 - 353
  • [33] ADDITIONAL INTRAPERITONEAL CISPLATIN/ETOPOSIDE TO FIRST-LINE CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN CANCER: THEINTERIM ANALYSISOF A RANDOMIZED PHASE II STUDY
    Zang, R. Y.
    Yu, J. J.
    Dai, Z. Y.
    Jiang, R.
    Zhang, Y. Q.
    Wang, H. Y.
    Tang, J.
    Cheng, X.
    Cai, S. M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [34] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    du Bois, A
    Lück, HJ
    Meier, W
    Adams, HP
    Möbus, V
    Costa, S
    Bauknecht, T
    Richter, B
    Warm, M
    Schröder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    Emons, G
    Wagner, U
    Kuhn, W
    Pfisterer, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) : 1320 - 1330
  • [35] ADDITIONAL INTRAPERITONEAL CISPLATIN/ETOPOSIDE TO FIRST-LINE CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN CANCER: The PRELIMINARY ANALYSIS OF A RANDOMIZED PHASE II STUDY
    Jiang, R.
    Yu, J.
    Dai, Z.
    Shen, Y.
    Zhang, Y.
    Tu, R.
    Wang, H.
    Tang, J.
    Yang, H.
    Cheng, X.
    Tu, D.
    Jia, H.
    Cai, S.
    Zang, R.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 736 - 736
  • [36] Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients
    Chambers, SK
    Chambers, JT
    Davis, CA
    Kohorn, EI
    Schwartz, PE
    Lorber, MI
    Handschumacher, RE
    Pizzorno, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1945 - 1952
  • [37] A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study
    Pignata, Sandro
    Breda, Enrico
    Scambia, Giovanni
    Pisano, Carmela
    Zagonel, Vittorina
    Lorusso, Domenica
    Greggi, Stefano
    De Vivo, Rocco
    Ferrandina, Gabriella
    Gallo, Ciro
    Perrone, Francesco
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (03) : 229 - 236
  • [38] Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer
    Ngoi, Natalie Y. L.
    Syn, Nicholas L. X.
    Goh, Robby M.
    Goh, Boon Cher
    Huang, Ruby Yun-Ju
    Soon, Yu Yang
    James, Elizabeth
    Cook, Adrian
    Clamp, Andrew
    Tan, David S. P.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (02):
  • [39] Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer.
    Blank, SV
    Curtin, JP
    Goldman, NA
    Fusco, E
    Lesko, Z
    Hochster, H
    Runowicz, CD
    Wadler, S
    Muggia, FM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 467S - 467S
  • [40] First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer:: A phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group
    du Bois, A
    Lück, HJ
    Bauknecht, T
    Meier, W
    Richter, B
    Kuhn, W
    Quaas, J
    Pfisterer, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 46 - 51
12345